ANAB - AnaptysBio • Dividends
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
See below the complete and updated table with all dividends paid and declared history, etc
The latest dividend from ANAB was $20.51 per share (ex-dividend 4/20/2026). The dividend yield over the last 12 months is 0%. Over the last 12 months there was 1 distribution, totalling $20.51 per share.